Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 11/2013

01-11-2013 | Original Article

Bisphosphonate use and subsequent hip fracture in South Korea

Authors: Y.-K. Lee, Y.-C. Ha, H. J. Choi, S. Jang, C. Park, Y.-T. Lim, C. S. Shin

Published in: Osteoporosis International | Issue 11/2013

Login to get access

Abstract

Summary

We determined the incidence of second hip fracture and evaluated whether compliant and persistent users of bisphosphonate had a lower incidence of second hip fracture after prior hip fracture, from a national claim registry.

Introduction

Bisphosphonate is prescribed worldwide for the primary prevention of osteoporotic fracture. However, the association between adherent use of bisphosphonate and prevention of second hip fracture is unclear. Our purpose was to determine whether the adherent use of bisphosphonate was associated with a decreased risk of second hip fracture in South Korea, using a nationwide database.

Methods

From 2007 to 2011, first and second hip fractures were identified using the ICD-10 and procedure code form from the nationwide database of the Health Insurance Review and Assessment Service. Compliant use of bisphosphonate was defined as a patient medication possession ratio of 80 or more. Persistent users were defined patients with a refill gap of 30 days or less. We compared the incidence of second hip fracture in compliant and persistent users and non-users.

Results

Among 59,782 patients with first hip fracture, in this study, 1,336 second hip fracture occurred after the initial hip fracture during the study period. The mean age at the first hip fracture was 75.4 years (range, 50 to 100 years). The cumulative 1-year, 2-year, and 3-year incidence of second hip fracture was 1.0 % (552/59,782), 1.9 % (1,123/59,782), and 2.2 % (1,336/59,782), respectively. After multivariate analysis, compliant and persistent use of bisphosphonate was significantly independent protectors for second hip fracture (HR, 0.595; 95 % CI, 0.400–0.885; HR, 0.433; 95 % CI, 0.327–0.573, respectively).

Conclusions

Compliant and persistent use of bisphosphonate decreases the risk of second hip fracture, in terms of secondary prevention.
Literature
1.
Park C, Ha YC, Jang S, Yoon HK, Lee YK (2011) The incidence and residual lifetime risk of osteoporosis-related fractures in Korea. J Bone Miner Metab 29:744–751PubMedCrossRef
2.
Salaffi F, Cimmino MA, Malavolta N, Carotti M, Di Matteo L, Scendoni P, Grassi W (2007) The burden of prevalent fractures on health-related quality of life in postmenopausal women with osteoporosis: the IMOF study. J Rheumatol 34:1551–1560PubMed
3.
Yoon HK, Park C, Jang S, Lee YK, Ha YC (2011) Incidence and mortality following hip fracture in Korea. J Korean Med Sci 26:1087–1092PubMedCrossRef
4.
Haentjens P, Autier P, Collins J, Velkeniers B, Vanderschueren D, Boonen S (2003) Colles fracture, spine fracture, and subsequent risk of hip fracture in men and women. A meta-analysis. J Bone Joint Surg Am 85-A:1936–1943PubMed
5.
Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733–759PubMedCrossRef
6.
Bilezikian JP (2009) Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am J Med 122:S14–S21PubMedCrossRef
7.
Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122:S3–S13PubMedCrossRef
8.
Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T (2012) GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int 23:223–231PubMedCrossRef
9.
Landfeldt E, Strom O, Robbins S, Borgstrom F (2012) Adherence to treatment of primary osteoporosis and its association to fractures—the Swedish Adherence Register Analysis (SARA). Osteoporos Int 23:433–443PubMedCrossRef
10.
Soong YK, Tsai KS, Huang HY, Yang RS, Chen JF, Wu PC, Huang KE (2013) Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan. Osteoporos Int 24(2):511–521. doi:10.​1007/​s00198-012-1984-z, Epub 2012 May 16PubMedCrossRef
11.
Gullberg B, Johnell O, Kanis JA (1997) World-wide projections for hip fracture. Osteoporos Int 7:407–413PubMedCrossRef
12.
Lau EM, Cooper C (1996) The epidemiology of osteoporosis. The oriental perspective in a world context. Clin Orthop Relat Res
13.
Ha YC, Kim SR, Koo KH, Yoon TR, Kim SY, Lee BJ, Hyun KC, Kim YS, Hwang SC, Hwang IH, Im I (2004) An epidemiological study of hip fracture in Jeju Island, Korea. J Korean Orthop Assoc 39:131–136
14.
Choi HJ, Shin CS, Ha YC, Jang SM, Jang SH, Park CM, Yoon HK, Lee SS (2011) Burden of osteoporosis in adults in Korea: a national health insurance database study. J Bone Miner Metab 30:54–58PubMedCrossRef
15.
16.
Lee YK, Ha YC, Park C, Yoo JJ, Shin CS, Koo KH (2013) Bisphosphonate use and increased incidence of subtrochanteric fracture in South Korea: results from the National Claim Registry. Osteoporos Int 24(2):707–711PubMedCrossRef
17.
18.
Dennison E, Mohamed MA, Cooper C (2006) Epidemiology of osteoporosis. Rheum Dis Clin North Am 32:617–629PubMedCrossRef
19.
Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, De Laet C, Jonsson B (2000) Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 11:669–674PubMedCrossRef
20.
Doherty DA, Sanders KM, Kotowicz MA, Prince RL (2001) Lifetime and five-year age-specific risks of first and subsequent osteoporotic fractures in postmenopausal women. Osteoporos Int 12:16–23PubMedCrossRef
21.
Kang HY, Yang KH, Kim YN, Moon SH, Choi WJ, Kang DR, Park SE (2010) Incidence and mortality of hip fracture among the elderly population in South Korea: a population-based study using the national health insurance claims data. BMC Publ Health 10:230CrossRef
22.
Gold DT, Martin BC, Frytak JR, Amonkar MM, Cosman F (2007) A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Curr Med Res Opin 23:585–594PubMedCrossRef
23.
Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013–1022PubMedCrossRef
24.
Birks YF, Hildreth R, Campbell P, Sharpe C, Torgerson DJ, Watt I (2003) Randomised controlled trial of hip protectors for the prevention of second hip fractures. Age Ageing 32:442–444PubMedCrossRef
25.
Berry SD, Samelson EJ, Hannan MT, McLean RR, Lu M, Cupples LA, Shaffer ML, Beiser AL, Kelly-Hayes M, Kiel DP (2007) Second hip fracture in older men and women: the Framingham study. Arch Intern Med 167:1971–1976PubMedCrossRef
26.
Lawrence TM, Wenn R, Boulton CT, Moran CG (2010) Age-specific incidence of first and second fractures of the hip. J Bone Joint Surg Br 92:258–261PubMed
27.
28.
Lee YK, Ha YC, Yoon BH, Koo KH (2012) Incidence of second hip fracture and compliant use of bisphosphonate. Osteoporos Int. Epub ahead of print.
29.
Follin SL, Black JN, McDermott MT (2003) Lack of diagnosis and treatment of osteoporosis in men and women after hip fracture. Pharmacotherapy 23:190–198PubMedCrossRef
30.
Formiga F, Rivera A, Nolla JM, Coscujuela A, Sole A, Pujol R (2005) Failure to treat osteoporosis and the risk of subsequent fractures in elderly patients with previous hip fracture: a five-year retrospective study. Aging Clin Exp Res 17:96–99PubMedCrossRef
31.
Rabenda V, Vanoverloop J, Fabri V, Mertens R, Sumkay F, Vannecke C, Deswaef A, Verpooten GA, Reginster JY (2008) Low incidence of anti-osteoporosis treatment after hip fracture. J Bone Joint Surg Am 90:2142–2148PubMedCrossRef
32.
Seeman E, Compston J, Adachi J, Brandi ML, Cooper C, Dawson-Hughes B, Jonsson B, Pols H, Cramer JA (2007) Non-compliance: the Achilles’' heel of anti-fracture efficacy. Osteoporos Int 18:711–719PubMedCrossRef
33.
Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003–1008PubMedCrossRef
34.
Kim SR, Ha YC, Park YG, Lee SR, Koo KH (2011) Orthopedic surgeon's awareness can improve osteoporosis treatment following hip fracture: a prospective cohort study. J Korean Med Sci 26:1501–1507PubMedCrossRef
35.
Wilson RK, Tomlinson G, Stas V, Ridout R, Mahomed N, Gross A, Cheung AM (2011) Male and non-english-speaking patients with fracture have poorer knowledge of osteoporosis. J Bone Joint Surg Am 93:766–774PubMedCrossRef
36.
Kamatari M, Koto S, Ozawa N, Urao C, Suzuki Y, Akasaka E, Yanagimoto K, Sakota K (2007) Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. J Bone Miner Metab 25:302–309PubMedCrossRef
37.
Kertes J, Dushenat M, Vesterman JL, Lemberger J, Bregman J, Friedman N (2008) Factors contributing to compliance with osteoporosis medication. Isr Med Assoc J 10:207–213PubMed
38.
Weycker D, Macarios D, Edelsberg J, Oster G (2007) Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int 18:271–277PubMedCrossRef
39.
Navarro RA, Greene DF, Burchette R, Funahashi T, Dell R (2011) Minimizing disparities in osteoporosis care of minorities with an electronic medical record care plan. Clin Orthop Relat Res 469:1931–1935PubMedCrossRef
40.
Bogoch ER, Elliot-Gibson V, Beaton DE, Jamal SA, Josse RG, Murray TM (2006) Effective initiation of osteoporosis diagnosis and treatment for patients with a fragility fracture in an orthopaedic environment. J Bone Joint Surg Am 88:25–34PubMedCrossRef
41.
Edwards BJ, Koval K, Bunta AD, Genuario K, Hahr A, Andruszyn L, Williams M (2011) Addressing secondary prevention of osteoporosis in fracture care: follow-up to "own the bone". J Bone Joint Surg Am 93:e871–e877CrossRef
42.
McLellan AR, Wolowacz SE, Zimovetz EA, Beard SM, Lock S, McCrink L, Adekunle F, Roberts D (2011) Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision. Osteoporos Int 22:2083–2098PubMedCrossRef
43.
McLellan AR, Gallacher SJ, Fraser M, McQuillian C (2003) The fracture liaison service: success of a program for the evaluation and management of patients with osteoporotic fracture. Osteoporos Int 14:1028–1034PubMedCrossRef
44.
Lih A, Nandapalan H, Kim M, Yap C, Lee P, Ganda K, Seibel MJ (2011) Targeted intervention reduces refracture rates in patients with incident non-vertebral osteoporotic fractures: a 4-year prospective controlled study. Osteoporos Int 22:849–858PubMedCrossRef
45.
Ganda K, Puech M, Chen JS, Speerin R, Bleasel J, Center JR, Eisman JA, March L, Seibel MJ (2013) Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta-analysis. Osteoporos Int 24(2):393–406. doi:10.​1007/​s00198-012-2090-y, Epub 2012 Jul 25PubMedCrossRef
46.
Egan M, Jaglal S, Byrne K, Wells J, Stolee P (2008) Factors associated with a second hip fracture: a systematic review. Clin Rehabil 22:272–282PubMedCrossRef
47.
Lee YK, Nho JH, Ha YC, Koo KH (2012) Persistence with intravenous zoledronate in elderly patients with osteoporosis. Osteoporos Int 23:2329–2333PubMedCrossRef
Metadata
Title
Bisphosphonate use and subsequent hip fracture in South Korea
Authors
Y.-K. Lee
Y.-C. Ha
H. J. Choi
S. Jang
C. Park
Y.-T. Lim
C. S. Shin
Publication date
01-11-2013
Publisher
Springer London
Published in
Osteoporosis International / Issue 11/2013
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-013-2395-5

Other articles of this Issue 11/2013

Osteoporosis International 11/2013 Go to the issue

Erratum

Erratum to: Direct healthcare costs for 5 years post-fracture in Canada

Original Article

Adherence to raloxifene therapy: assessment methods and relationship with efficacy

Original Article

Before and after hip fracture, vitamin D deficiency may not be treated sufficiently

Original Article

Bone mass, body composition and vitamin D status of ARV-naïve, urban, black South African women with HIV infection, stratified by CD4 count

Erratum

Erratum to: Correlation between 25-hydroxyvitamin D levels and latitude in Brazilian postmenopausal women: from the Arzoxifene Generations Trial

Original Article

Bone health and aldosterone excess